Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Can MCK overcome its sustaining challenges with robust finances and innovation?

Shares of McKesson Corp. MCK advanced 1.29% to $603.40 Monday, on what proved to be an all-around great trading session for ...

Buying $100 In MCK: If an investor had bought $100 of MCK stock 20 years ago, it would be worth $1,621.13 today based on a ...

Walmart, which is often dubbed the world’s biggest retailer in reference to its revenue, still leads the way when it comes to ...

The stock's fall snapped a three-day winning streak.

Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors ...

McKesson will purchase an 80% interest for approximately $850 million, while Prism Vision physicians will retain a 20% ...

McKesson (MCK) and AmerisourceBergen (ABC) are among the pharmaceutical wholesalers that have won a bid to dismiss antitrust allegations that ...

Q3 2025 Earnings Call Transcript February 5, 2025 Operator: Welcome to McKesson’s Third Quarter Fiscal 2025 Earnings ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the conference over to Rachel ...